Sonelokimab Delivers 81% Response in Phase 2 Axial Spondyloarthritis Trial
Sonelokimab achieved an 81% clinically meaningful response rate at Week 12 in the Phase 2 S-OLARIS trial, with rapid reductions in inflammatory mediators and no new safety signals. MoonLake ended Q4 with $394M cash, raised $75M equity and drew $25M debt, funding operations into H2 2027.
1. Phase 2 Trial Success
Sonelokimab produced an 81% clinically meaningful response at Week 12 in the Phase 2 S-OLARIS trial for axial spondyloarthritis, demonstrating rapid reductions in key inflammatory mediators and osteoblast activity. No new safety signals were detected, and the drug’s safety profile remained consistent with prior studies.
2. Cash Position and Runway
MoonLake ended the fourth quarter with $394M in cash and cash equivalents, raised $75M through its latest equity issuance and drew $25M under its amended debt facility. These funds, along with up to $400M in remaining non-dilutive financing, are expected to support operations into the second half of 2027.
3. Analyst Ratings and Technical Outlook
Analysts maintain a Buy consensus with an average price target of $40. Technical indicators show the stock trading below its 20-day and 100-day moving averages, a neutral RSI of 44.45, key support at $15 and resistance at $20, suggesting cautious investor sentiment.